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Abstract Matrix metalloproteinases (MMPs) and the specific
tissue inhibitors of metalloproteinases (TIMPs) are involved in
tissue turnover in normal and pathological processes including
wound healing. Marimastat, a potent inhibitor of MMPs, was
used to investigate the role of MMPs in an in vitro wound
contraction model, the dermal equivalent, in which fibroblasts are
grown in a collagen matrix. Marimastat inhibited fibroblast-
mediated lattice contraction and this inhibition was reversible
upon removal of the inhibitor, indicating that MMPs play an
important role in fibroblast-mediated collagen lattice contrac-
tion, modelling what may happen when granulation tissue
contracts in a healing wound.
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1. Introduction
The dermal equivalent (DE) model consists of dermal ¢bro-
blasts grown in a hydrated native collagen lattice and o¡ers
an environment in which to observe ¢broblast behaviour in
physiologically relevant conditions similar to those in dermis.
Fibroblasts cultured within such a collagen matrix are ob-
served to reorganise the collagen ¢brils and contract the ma-
trix [1]. This model has several advantages over monolayer
culture (in which ¢broblasts are known to behave di¡erently
in many respects) and is now widely used as a simpli¢ed, in
vitro model of dermis. This system also has therapeutic po-
tential for grafting [2]. Many researchers have studied ¢bro-
blast-mediated lattice contraction and more generally have
used the DE model to investigate cell-matrix interactions,
for example as a model for wound healing [3^6]. In the course
of wound healing, ¢broblasts invade the wound space and not
only secrete collagen and glycosaminoglycans, but also pro-
duce matrix metalloproteinases (MMPs) that control the re-
modelling of the newly formed granulation tissue [7]. At least
one metalloproteinase, MMP-1, is also produced by keratino-
cytes during wound healing and may be involved in the proc-
ess of re-epithelialisation.
MMPs form a group of extracellular proteinases that share
several common characteristics [8]. Each MMP degrades at
least one component of the extracellular matrix (ECM) and
in fact with the exception of MMP-1, 8 and 13 (the collage-
nases), most have a broad substrate speci¢city. To be catalyti-
cally active, MMPs must contain a zinc ion within the active
site and functional stability is conferred by a secondary zinc
ion and calcium ions [9]. MMP-1 degrades collagen by a sin-
gle speci¢c cleavage per chain that allows partial unwinding of
the triple helical structure [10]. This results in the formation of
a denatured gelatin structure which is susceptible to further
attack by other members of the MMP family [11].
MMPs are secreted as latent enzymes requiring proteolytic
cleavage or some other modi¢cation (e.g. treatment with sul-
phydryl reagents) for activation [11^13] and their activity is
speci¢cally controlled by extracellular proteins, tissue inhibi-
tors of metalloproteinases (TIMPs). The function of these is
now beginning to be understood and to date four human
TIMPs have been characterised [14]. TIMPs are 28 kDa gly-
coproteins with a 21 kDa protein core that are secreted by
¢broblasts as well as other cells, that also produce MMPs,
and which bind non-covalently to active MMPs in a 1:1 mo-
lar ratio [11^13]. TIMP production is regulated by agents such
as growth factors [8].
To investigate the role that MMP activity may play in
collagen lattice contraction in vitro as a model of wound
contraction in vivo, a speci¢c MMP inhibitor, Marimastat,
was used. This is one of a range of synthetic compounds
designed to bind tightly to the zinc atoms in the active site
of MMPs, thus disabling the enzymes and blocking their func-
tion. Marimastat has a peptido-mimetic backbone to facilitate
binding to the active site of MMP, and a hydroxamate struc-
ture to chelate the zinc ion [15].
2. Materials and methods
2.1. Materials
Marimastat was synthesised by SmithKline Beecham, Harlow, UK.
[3H]Acetic anhydride (speci¢c activity 50 mCi/mmol) was purchased
from New England Nuclear Research Products, Stevenage, UK. Acid-
soluble type I collagen from calf skin for the MMP-1 activity assay,
1,4-dioxane, trypsin, APMA and EDTA were purchased from Sigma
Chemical Co., Poole, UK. DMEM, NBCS, penicillin (5000 U/ml) and
streptomycin (5000 Wg/ml) were purchased from Gibco, Paisley, UK.
2.2. Cell culture
Monolayer cultures of primary human adult dermal ¢broblasts
were established from collagenase-treated dermis [16]. Fibroblasts
were grown in monolayer culture in 1UDMEM supplemented with
5% (v/v) NBCS and used between passages 5 and 10. Prior to for-
mation of dermal equivalents the cell monolayers were washed twice
with PBS and detached by treatment with 0.05% (w/v) trypsin-0.02%
(w/v) EDTA in PBS. Cells were washed with DMEM containing 5%
(v/v) NBCS and were pelleted by centrifugation at 100Ug in an MSE
bench top centrifuge for 5 min at room temperature. A viable cell
count was determined using 0.4% (w/v) trypan blue. Fibroblasts were
resuspended in DMEM at a density of 2.5U105 cells per ml.
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2.3. Dermal equivalents
DEs were fabricated essentially as described by Bell and co-workers
[1] using type I collagen extracted from rat tail [16]. DEs were pre-
pared by the addition of 4 ml 2UDMEM, 3 ml of 5 mg/ml collagen in
13 mM HCl and 1 ml of 0.1 M NaOH to 1 ml of cell suspension (¢nal
concentration 1.5 mg/ml collagen). The DE suspension was swirled to
mix and 800 Wl was pipetted into each well of a 12-well tissue culture
plate to give 2U104 cells per well. The plate was incubated at 37‡C to
allow gel formation and then DEs were always incubated in 1UD-
MEM containing 5% (v/v) NBCS.
Unless otherwise stated, Marimastat in DMSO was added to DEs
at a ¢nal concentration of 1 or 10 WM immediately after polymer-
isation in 1 ml medium. Toxicity studies indicated that Marimastat at
concentrations below 15 WM did not a¡ect ¢broblast viability as
measured by the tetrazolium (MTT) assay [17] (data not shown).
DEs were subsequently detached from the walls of the culture plate
3 days (unless otherwise stated) after polymerisation by ‘ringing’ with
a pasteur pipette. Fresh medium with and without Marimastat was
added and subsequently changed every 48 h following DE detach-
ment. Lattice contraction was measured by determining the diameter
of the DE using a ruler.
2.4. Assay for MMP-1 activity
Commercially available acid-soluble type I collagen from calf skin
was radiolabelled using [3H]acetic anhydride as described previously
[18]. 5UMMP-1 assay bu¡er (250 mM Tris-HCl pH 7.4, 1 M NaCl,
25 mM CaCl2) was added to 3 Wg radiolabelled collagen in 13 mM
HCl (speci¢c activity 1.45U106 cpm/mg) to raise the solution to neu-
tral pH yielding ¢nal concentrations of 50 mM Tris-HCl pH 7.4, 200
mM NaCl and 5 mM CaCl2. Fibroblast-conditioned medium in
1UMMP-1 assay bu¡er was incubated with the neutralised radiola-
belled collagen solution for 20 h at room temperature. To stop the
reaction 20 mM EDTA was added. To activate latent MMP-1, sam-
ples were incubated with the 3H-labelled collagen in the presence of
1 mM APMA.
For each experiment a negative control containing 20 mM EDTA
to inhibit MMP activity was included in which typically less than 4%
of the total radioactivity present was released. The samples were
mixed with 1 volume of 1,4-dioxane to precipitate native collagenous
material and placed on ice for 10 min. The tubes were then centri-
fuged for 10 min at 12 000Ug in a microfuge at 4‡C to pellet undi-
gested collagen. The amount of digested collagen was determined by
removing the supernatant and determining the radioactivity by scin-
tillation counting. For each time point ¢ve replicates were used to
determine the radioactivity released into solution and the linear re-
sponse region was used. The radioactivity measured in the negative
control was subtracted from each sample to allow a measurement of
proteolysis of collagen by MMP-1.
3. Results
3.1. MMP-1 activity produced by ¢broblasts is inhibited by
Marimastat
Fig. 1 shows the e¡ect of Marimastat on the measured
MMP-1 activity in the ¢rst 8 h after DE fabrication. In con-
trol DEs the MMP-1 activity began to rise, detectable 4 h
after polymerisation, and increased linearly from this point.
The measured MMP-1 activity in Marimastat-treated DEs in
contrast was almost zero throughout this time course at both
Marimastat concentrations used. Fig. 2 shows the measured
MMP-1 activity 1 and 3 days after DE detachment. It can be
seen that 1 day after detachment MMP-1 activity was com-
pletely inhibited at both concentrations of Marimastat. After
3 days the level of MMP-1 activity had increased two-fold in
control DEs. A concentration of 1 WM Marimastat produced
a 60% inhibition of MMP-1 activity, whereas MMP-1 activity
was 90% inhibited in DEs incubated with 10 WM Marimastat,
after 3 days. Partial inhibition of MMP-1 activity with 1 WM
Marimastat correlated with the partial inhibition of ¢broblast-
mediated lattice contraction observed (see Fig. 3).
3.2. Marimastat inhibits ¢broblast-mediated lattice contraction
Fig. 3 shows the e¡ect of Marimastat on DE contraction.
Under the conditions used, control DEs contracted, typically
with approx. 40% of the contraction occurring during the ¢rst
4 days. In the presence of 10 WM Marimastat, lattice contrac-
tion was completely inhibited. Incubation with 1 WM Marima-
stat resulted in a similar contraction pattern to that observed
in control DEs but occurred at a slower rate resulting in only
25% contraction after 4 days in culture.
To establish whether the e¡ect of Marimastat could be
reversed after 5 days in culture, the medium was aspirated
and the DEs were washed twice with 1UDMEM for 1 h
and then incubated in medium without Marimastat. The me-
dium was replaced every 24 h to ensure that any residual
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Fig. 1. E¡ect of Marimastat on MMP-1 activity after DE fabrica-
tion. DEs were incubated in the presence of 0, 1 or 10 WM Marima-
stat following fabrication. Samples of DE conditioned medium were
removed at intervals after fabrication and assayed for MMP-1 activ-
ity as described in Section 2. Results are expressed as pg collagen
degraded/min þ S.E.M. of ¢ve replicates. F, control; b, 1 WM; O,
10 WM.
Fig. 2. E¡ect of Marimastat on MMP-1 activity after DE detach-
ment. DEs were incubated in the presence of 0, 1 or 10 WM Mari-
mastat following fabrication. DEs were detached after 3 days in cul-
ture. Samples of DE conditioned medium were removed at 1 and 3
days after detachment and assayed for MMP-1 activity as described
in Section 2. Results are expressed as pg collagen degraded/min þ
S.E.M. of ¢ve replicates. Open bars, 1 day and solid bars, 3 days
after DE contraction (absence of bar is equivalent to no measurable
activity).
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Marimastat trapped within the collagen lattice was eventually
removed.
Removal of Marimastat after 5 days in culture resulted in
the reversal of the inhibition of contraction. DEs which had
been cultured with 10 WM Marimastat immediately began to
contract at a rapid rate. The rate of contraction was even
greater in DEs that had been incubated with 1 WM Marima-
stat to result in almost the same size lattices as control ones
after 9 days in culture.
Fibroblasts released from the plastic of culture plates by
trypsinisation need to attach to a new substrate and spread
before they can proliferate and begin other activities. In order
to investigate whether Marimastat was impairing initial ¢bro-
blast spreading in the collagen lattice which then resulted in
an inhibition of contraction, DEs were prepared and the ex-
periment was repeated exactly as described in Section 2 except
that for the ¢rst 24 h after lattice fabrication the DEs were
incubated in medium without Marimastat. After 24 h incuba-
tion the medium was replaced with medium with 0, 1 or 10
WM Marimastat. The DEs were incubated for a further 48 h
before the lattices were detached. A similar pattern of Mar-
imastat inhibition of contraction was observed to that previ-
ously seen in Fig. 3 (data not shown).
To investigate whether Marimastat inhibited cell attach-
ment ¢broblasts were seeded onto glass coverslips in ¢broblast
medium containing 1 or 10 WM Marimastat. Cell attachment
and cell spreading were examined microscopically after 4 h
and 48 h. Marimastat inhibited cell attachment after 4 h in-
cubation but after 48 h the ¢broblasts had spread out indicat-
ing that Marimastat can initially retard cell attachment (data
not shown).
4. Discussion
Many attempts have been made to identify and isolate the
factors required for ¢broblast-mediated lattice contraction
such as occurs in wound contraction and which is modelled
by the DE system [19^21]. Fibroblast-mediated gel contrac-
tion in DEs is biphasic [22] : there is an initial phase of rapid
contraction followed by a subsequent period of slower con-
traction and this was observed in the present work. Investi-
gation of the role of MMP-1 in DE contraction using radio-
labelled collagen [22] showed that during the ¢rst 24 h after
fabrication radioactivity was being released into the culture
medium implying that the ‘remodelling’ of collagen ¢bres was
occurring. The enzymic activity of MMPs in a tissue or in a
model system such as the DE, is dependent on the concen-
tration of TIMPs present. In the model system activation of
MMP-1 by APMA results in the production of active enzyme
to which TIMP-1, if present, will bind instantly to form an
enzyme:inhibitor complex [18]. Degradation of [3H]collagen is
therefore due only to MMP-1 molecules not bound to TIMP-
1. Release of MMP-1 into the medium is an indication of the
production of MMP-1 as it is well established that activation
of MMPs occurs close to the cell allowing ‘focalised’ proteol-
ysis, even in the presence of high concentrations of inhibitors
[23]. Although other MMPs may degrade type I collagen to a
limited extent, in the dermal equivalent fabricated using native
collagen as reported in the present work, MMP-1 is the most
likely candidate.
We have shown that MMP-1 production increases during
normal collagen lattice contraction and that typically the
amount of active enzyme detectable under the conditions de-
scribed here is approx. 15% of the total potential MMP-1
activity (data not shown). The presence of 10 WM Marimastat
inhibited both MMP-1 activity and collagen lattice contrac-
tion. Partial lattice contraction was observed in DEs treated
with 1 WM Marimastat and this correlated with 60% inhibi-
tion of MMP-1 activity. Upon removal of Marimastat from
the medium by washing out, the DEs then contracted after a
short lag phase. This con¢rmed that the ¢broblasts seeded
into these lattices had remained viable throughout the treat-
ment.
Previous studies have shown that the time course of colla-
gen gel reorganisation correlates with extent of initial cell
spreading, and that cells which spread poorly because of cy-
toskeletal or other defects, have a decreased ability to cause
lattice contraction [4,20]. Marimastat initially reduced cell at-
tachment but subsequent ¢broblast spreading was not com-
promised by Marimastat. Fibroblasts allowed to spread in the
collagen lattice for 24 h prior to addition of Marimastat and
lattice contraction showed a similar pattern of lattice contrac-
tion inhibition. This indicated that impaired ¢broblast attach-
ment and spreading was not a signi¢cant factor in the inhib-
ition of contraction by Marimastat. It is also unlikely that
Marimastat exerts its action by inhibiting cell proliferation
since cell numbers in DEs do not begin to increase until after
6 days in culture under the conditions used here (data not
shown) although it is well established that inhibition of cell
attachment inhibits cell proliferation [24].
It should be noted that the concentrations of Marimastat
used in this study are in the WM range and yet the Ki is 5^8
nM [25]. It is possible that the accessibility of the compound
to the ¢broblasts may be impaired by the surrounding colla-
gen matrix. For example, Marimastat may have become
trapped within, or bound to, components in the lattice, or
may not get close enough to the active site on collagenase
unless much higher concentrations are used. Another possibil-
ity is that a di¡erent metalloprotease which may play a more
important role in ¢broblast-mediated lattice contraction was
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Fig. 3. E¡ect of Marimastat on ¢broblast-mediated lattice contrac-
tion. DEs were incubated in the presence of 0, 1 or 10 WM Marima-
stat following fabrication. DEs were detached after 3 days in cul-
ture. Lattice diameter was measured every 24 h. After 5 days
following detachment Marimastat was removed, DEs were washed
and incubated in medium without Marimastat. Results are expressed
as mean lattice diameter þ S.E.M. of four replicates. F, control; b,
1 WM; O, 10 WM.
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inhibited and that higher concentrations of Marimastat were
required to ensure complete inhibition.
We have shown that Marimastat, a potent inhibitor of
MMPs, can retard or stop ¢broblast-mediated collagen lattice
contraction. The viability of ¢broblasts within the collagen
lattice was not a¡ected and inhibition of cell spreading did
not play a role in contraction inhibition. This study has
shown that the presence of exogenously added MMP inhib-
itors may have a potential use for treating chronic wounds
where the correct balance of enzyme to inhibitor has been
lost, or to prevent rapid contraction of burn wounds to reduce
scarring.
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